DUBLIN, Oct. 21, 2020 /PRNewswire/ — The «Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020» report has been added to ResearchAndMarkets.com’s offering.
Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 provides details of the latest option and evaluation agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of option and evaluation agreements from 2014 to 2020.
There are two major forms of deal term that allow a party to a deal to secure rights to an asset subject to a future event namely, option and evaluation.
Evaluation agreements allow a party to the deal to obtain rights to a technology or compound, subject to a period of time to evaluate the quality, scope and applicability of the technology to its intended endpoint. Normally the technology is at an early stage and/or unproven and the partnering company wishes to assess the technology as part of the due diligence process in advance of signing a long term licensing agreement.
Evaluation agreements have been a mainstay of technology licensing from the earliest days.
An option agreement differs in that the option is often an integral part of an agreement already entered by the parties, providing the party with the option right to retain or extend certain rights to the technology already partnered.
Option agreements are becoming increasingly popular as they create additional flexibility within a deal for additional rights that the parties do not wish to commit at the outset of the agreement.
This report focuses on option and evaluation agreements and clauses within broader agreements between big pharma-big pharma, big pharma – smaller company, and smaller company-smaller company, providing a detailed insight into all such deals.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous tables and figures that illustrate the trends and activities in option and evaluation dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.
- In-depth understanding of option and evaluation deal trends since 2014
- Analysis of the structure of option and evaluation agreements with numerous real life case studies
- Comprehensive access to over 1,000 actual option and evaluation deals entered into by the world’s biopharma companies
- Detailed access to actual option and evaluation contracts enter into by the leading fifty big pharma companies
- Insight into the terms included in a option and evaluation agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology type
Key Topics Covered:
Chapter 1 – Introduction
Chapter 2 – Trends in option and evaluation dealmaking
2.2. Difference between option and evaluation deals
2.2.1. Types of option agreement
2.3. Trends in option and evaluation deals since 2014
2.3.1. Option and evaluation dealmaking by year since 2014
2.3.2. Option and evaluation dealmaking by phase of development since 2014
2.3.3. Option and evaluation dealmaking by industry sector since 2014
2.3.4. Option and evaluation dealmaking by therapy area since 2014
2.3.5. Option and evaluation dealmaking by technology type since 2014
2.3.6. Option and evaluation dealmaking by most active company since 2014
2.4. Option-based deals
2.4.1. Attributes of option-based deals
2.4.2. Reasons for entering an option-based deal
2.4.3. Uptake of option exercise
2.4.4.The future of option-based deals
2.5. Co-promotion options
2.5.1. Attributes of co-promotion in multi-component deals
2.5.2. Reasons for including co-promotion options in a deal
2.5.3. Uptake of co-promotion rights
2.5.4. Co-promotion rights as bargaining chips
2.5.5. The future of co-promotion as part of multicomponent deals
2.6. Company acquisition options
2.6.1. Case study 1: Cephalon – Ception
2.6.2. Case study 2: Endo – Indevus
2.6.3. The future of option to acquire deals
Chapter 3 – Overview of option and evaluation deal structure
3.2. Option and evaluation agreement structure
3.2. Example evaluation agreements
3.2.1.a. Case study 3: Idenix Pharmaceuticals – Janssen Pharmaceuticals
3.3. Option agreement structure
3.3.1. Example option agreements
3.3.1.a. Option to license
Case study 4: Biogen Idec – Isis Pharmaceuticals
3.3.1.b. Option to extend/expand applications/territories
Case study 5: Novartis -Prometheus
3.3.1.c. Option to finance
Case study 6: Amarantus BioSciences – Power3 Medical Products
3.3.1.d. Option to co-promote
Case study 7: Teva – OncoGenex Pharmaceuticals
3.3.1.e. Option to manufacture/supply
Case study 8: NPS Allelix – Nycomed
3.4. Option to acquire agreement structure
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 9: ViroPharma – Meritage Pharma
3.4.1.b. Case study 10: Nuvasive – Progentix Orthobiology
Chapter 4 – Leading option and evaluation deals
4.2. Top option and evaluation deals by value
Chapter 5 – Top 25 most active option and evaluation dealmakers
5.2. Top 25 most active option and evaluation dealmakers
Chapter 6 – Option and evaluation contracts directory
6.2. Option andevaluation deals with contracts since 2014
Appendix 1 – Option and evaluation dealmaking by companies A-Z
Appendix 2 – Option and evaluation dealmaking by industry sector
Appendix 3 – Option and evaluation dealmaking by stage of development
Appendix 4 – Option and evaluation dealmaking by therapy area
Appendix 5 – Option and evaluation dealmaking by technology type
For more information about this report visit https://www.researchandmarkets.com/r/dzdaut
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets